The Icahn School of Medicine at Mount Sinai Partners with Genisphere to Develop Rapid, High-Throughput Allergy Test
January 31, 2013 – The Icahn School of Medicine at Mount Sinai and Genisphere have agreed to jointly develop a new allergy test that will quickly and effectively characterize patients’ food allergies. The peptide-bead-based test will be high-throughput, semi-automatic and accurate, surpassing …
Anti-Cancer Activity Drug IRX4204 Shows Promise as a Potential Disease-Modifying Agent for Alzheimer’s Disease
September 13, 2012 – New research presented today at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco, California demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer’s disease. The presentation entitled “Investigation …
Mount Sinai Researchers Develop New Computational Method to Find Novel Connections from Gene to Gene, Drug to Drug and Between Scientists
July 23, 2012 – Researchers from Mount Sinai School of Medicine have developed a new computational method that will help organize scientific data, making it easier for scientists to identify and prioritize genes, drug targets, and connections between drugs. By mining large …
Mount Sinai School of Medicine and PATH Agree To Collaborate on Novel Influenza Vaccine Research
July 16, 2012 – Mount Sinai School of Medicine (MSSM) and PATH have reached an agreement to partner on new vaccine research aimed at eliciting broadly-protective immunity against influenza viruses. The collaboration seeks to develop promising influenza vaccines that can be made available …
Mount Sinai Researchers Develop A Multi-Target Approach To Treating Tumors
June 7, 2012 – Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound …
Partnership Investment Fund Awards $1M to Support Four Promising Biomedical Products
June 4, 2012 – The Partnership for New York City (PFNYC) today announced that four local scientists have been awarded a total of $1 million to fund the final stages of research on new biomedical products that will be developed in the …
Ivan Galanin Appointed to Head Commercial Development at Mount Sinai School of Medicine’s Office of Technology and Business Development
April 10, 2012 – Ivan Galanin, an experienced research and development strategist, has joined Mount Sinai School of Medicine as Director of Commercial Development in the Office of Technology and Business Development. His appointment will begin April 9, 2012. Reporting to Teri …
CommonMind Consortium Launched as a Public-Private Effort to Generate and Broadly Share Molecular Data on Neuropsychiatric Disease
April 9, 2012 – Sage Bionetworks, Mount Sinai School of Medicine (MSSM), University of Pennsylvania (Penn), the National Institute of Mental Health (NIMH), and Takeda Pharmaceuticals Company Limited (TAKEDA) have launched a Public-Private Pre-Competitive Consortium to generate and analyze large-scale genomic data …
Mount Sinai School of Medicine and MRC Technology To Collaborate On Monoclonal Antibody Production and Humanization
April 3, 2012 – The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom’s prestigious Medical Research Council, have reached an agreement to collaborate on the development of monoclonal antibodies that can be commercialized as …